Cargando…
Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
PURPOSE: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. PATIE...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548219/ https://www.ncbi.nlm.nih.gov/pubmed/33116830 http://dx.doi.org/10.2147/CMAR.S276519 |
_version_ | 1783592578372861952 |
---|---|
author | Metz, David C Liu, Eric Joish, Vijay N Huynh, Lynn Totev, Todor I Duh, Mei Sheng Seth, Kiernan Giacalone, Susan Lapuerta, Pablo Morse, Michael A |
author_facet | Metz, David C Liu, Eric Joish, Vijay N Huynh, Lynn Totev, Todor I Duh, Mei Sheng Seth, Kiernan Giacalone, Susan Lapuerta, Pablo Morse, Michael A |
author_sort | Metz, David C |
collection | PubMed |
description | PURPOSE: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. PATIENTS AND METHODS: This was a retrospective, single arm, pre-post medical chart review of patients with locally advanced or metastatic neuroendocrine tumors and documented carcinoid syndrome receiving telotristat ethyl for at least 6 months. Patients with poorly differentiated tumors, mixed tumor types or conflicting clinical trial enrollment were excluded. Descriptive statistics, Kaplan–Meier and chi-square tests were used to evaluate PFS, tumor progression, changes in symptoms, body weight and ECOG performance status before and after telotristat ethyl initiation. Subgroup analyses were conducted in patients with the same pre- and post-telotristat ethyl background treatment. RESULTS: Anonymized data for 200 patients were provided by 114 physicians; patients received telotristat ethyl for a median of 9 months. Median time to tumor progression was 39.8 months (IQR, 18.7–39.8); most had no tumor progression at 6 (92%) and 12 months (87%). Median progression-free survival was 23.7 months (17.8–39.8); most had progression-free survival at 6 (90%) and 12 months (80%). Results were consistent in the subgroup of 65 patients with the same pre/post background treatment. Nearly all patients had improved carcinoid syndrome symptoms, stable or improved weight and ECOG performance status. CONCLUSION: Patients showed improvements in clinical outcomes and indicators of overall health following treatment with telotristat ethyl in this exploratory pilot study, consistent with previously observed reductions in tumor size. |
format | Online Article Text |
id | pubmed-7548219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75482192020-10-27 Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome Metz, David C Liu, Eric Joish, Vijay N Huynh, Lynn Totev, Todor I Duh, Mei Sheng Seth, Kiernan Giacalone, Susan Lapuerta, Pablo Morse, Michael A Cancer Manag Res Original Research PURPOSE: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. PATIENTS AND METHODS: This was a retrospective, single arm, pre-post medical chart review of patients with locally advanced or metastatic neuroendocrine tumors and documented carcinoid syndrome receiving telotristat ethyl for at least 6 months. Patients with poorly differentiated tumors, mixed tumor types or conflicting clinical trial enrollment were excluded. Descriptive statistics, Kaplan–Meier and chi-square tests were used to evaluate PFS, tumor progression, changes in symptoms, body weight and ECOG performance status before and after telotristat ethyl initiation. Subgroup analyses were conducted in patients with the same pre- and post-telotristat ethyl background treatment. RESULTS: Anonymized data for 200 patients were provided by 114 physicians; patients received telotristat ethyl for a median of 9 months. Median time to tumor progression was 39.8 months (IQR, 18.7–39.8); most had no tumor progression at 6 (92%) and 12 months (87%). Median progression-free survival was 23.7 months (17.8–39.8); most had progression-free survival at 6 (90%) and 12 months (80%). Results were consistent in the subgroup of 65 patients with the same pre/post background treatment. Nearly all patients had improved carcinoid syndrome symptoms, stable or improved weight and ECOG performance status. CONCLUSION: Patients showed improvements in clinical outcomes and indicators of overall health following treatment with telotristat ethyl in this exploratory pilot study, consistent with previously observed reductions in tumor size. Dove 2020-10-07 /pmc/articles/PMC7548219/ /pubmed/33116830 http://dx.doi.org/10.2147/CMAR.S276519 Text en © 2020 Metz et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Metz, David C Liu, Eric Joish, Vijay N Huynh, Lynn Totev, Todor I Duh, Mei Sheng Seth, Kiernan Giacalone, Susan Lapuerta, Pablo Morse, Michael A Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome |
title | Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome |
title_full | Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome |
title_fullStr | Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome |
title_full_unstemmed | Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome |
title_short | Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome |
title_sort | survival and clinical outcomes with telotristat ethyl in patients with carcinoid syndrome |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548219/ https://www.ncbi.nlm.nih.gov/pubmed/33116830 http://dx.doi.org/10.2147/CMAR.S276519 |
work_keys_str_mv | AT metzdavidc survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome AT liueric survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome AT joishvijayn survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome AT huynhlynn survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome AT totevtodori survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome AT duhmeisheng survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome AT sethkiernan survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome AT giacalonesusan survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome AT lapuertapablo survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome AT morsemichaela survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome |